Guardant Health Shares Fall After FDA Raises Concerns on AstraZeneca Breast Cancer Drug
Guardant stock fell after FDA raised doubts on a key drug study. Delay fears hurt short-term, but long-term outlook still strong.
/ 3 items
#GH↓
FDA Approves Guardant360 CDx for BRAF-Mutant Colorectal Cancer
Guardant Health’s Guardant360 CDx is now FDA-approved to identify BRAF V600E-mutant colorectal cancer patients, helping guide targeted therapy quickly with a simple blood test.
Guardant Health Beats Q3 Expectations, Raises Full-Year Revenue Guidance on Strong Oncology Growth
Guardant Health reports 39% revenue growth in Q3 2025, narrows losses, and increases full-year guidance to $965-970M driven by oncology expansion and Shield screening test adoption.